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Abstract 
A 42-year-old woman with SLE was admitted to our hospital because of severe anemia. 
Her bone marrow was almost normocellular and erythroblasts were nearly absent. 
Laboratory data showed elevated levels of lactate dehydrogenase and positive findings 
on Coombs’ tests. Based on these findings, her anemia was diagnosed as the overlap of 
PRCA with AIHA. Radioimmunoprecipitation assay revealed that her serum was 
positive for anti-erythropoietin antibodies before therapy. Furthermore, the 
autoantibodies inhibited proliferation of an EPO-dependent cell line in a 
dose-dependent manner. Immunosuppressive treatment improved the anemia 
accompanied with disappearance of the autoantibodies.  
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Introduction 
Systemic lupus erythematosus (SLE) is a multiorgan disorder that commonly involves 
the hematological system [1]. Among hematological complications, anemia is common 
under such mechanisms of induction as anemia of chronic disease (ACD), iron deficiency 
anemia (IDA), autoimmune hemolytic anemia (AIHA), anemia of chronic renal 
insufficiency and drug-induced myelotoxicity [1, 2]. In addition, anemia in SLE may be 
accompanied by various syndromes of hematopoietic failure, such as aplastic anemia, 
hemophagocytic syndrome and rare pure red cell aplasia (PRCA) [1, 2]. 
 We encountered a case of SLE accompanied with combined PRCA and AIHA, which is 
extremely rare. While searching for a mechanism responsible for the anemia in this 
case, anti-erythropoietin (EPO) autoantibodies were detected in the patient’s serum. In 
1997, Casadevall et al. reported the presence of autoantibody to EPO in a patient with 
transient PRCA who had anemia with erythroid hypoplasia [3]. In their patient, 
anti-EPO antibodies functionally blocked the interaction between EPO and EPO 
receptor, and were thus responsible for the impaired erythropoiesis [3]. The serum from 
our patient also inhibited EPO-dependent cell proliferation, suggesting that the anemia 
in this case may also be mediated by anti-EPO antibodies as one of its immunological 
mechanisms. This is the first case report of SLE with PRCA and AIHA associated with 
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functional anti-EPO autoantibodies. 
 
Case report 
A 42-year-old woman was admitted to hospital in November 1992 because of fatigue 
with severe anemia. She was first described as having thrombocytopenia in 1991. 
Thereafter, a diagnosis of SLE was made, based on the presence of bicytopenia and 
anti-nuclear antibody, elevated anti-DNA antibody titer and proteinuria in accordance 
with the American College of Rheumatology criteria for SLE [4]. There was no history of 
fever, rash or exposure to drugs or toxic agents thought to interact with erythrocytes or 
erythroblasts. Physical examination showed that her palpebral conjunctiva was anemic. 
Systemic computed tomographic scans showed no evidence of solid tumor, thymoma, or 
lymphadenopahty. The laboratory examination revealed marked anemia (red-cell count 
2.67×106/mm3, hemoglobin level 7.8 g/dl, reticulocyte count 1.3×104/mm3) and 
thrombocytopenia (platelet count 9.2×104/mm3). The erythrocyte sedimentation rate 
was 80 mm/h. Electrophoresis of serum proteins showed polyclonal gammopathy with a 
total gamma globulin concentration of 2.4 g/dl. The serum iron and ferritin levels were 
normal and elevated (157.8 ng/ml), respectively. C3 and C4 complement components 
were reduced. Direct and indirect Coombs’ tests gave positive results with an elevation 
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of lactate dehydrogenase (540 IU/l). The serum EPO level was elevated at 585.0 MIU/ml. 
Anti-nuclear, anti-ds DNA and anti-platelet antibodies were positive. Anti-U1 RNP, 
anti-Sm and anti-phospholipid antibodies were all negative. Serology for human 
immunodeficiency virus, hepatitis, cytomegalovirus, Epstein-Barr virus, and parvovirus 
B19 was negative. The prothrombin time, activated partial thromboplastin time and 
fibrinogen level were all normal. Although renal function was normal, 24-h urinary 
protein excretion was 0.5 g. Bone marrow aspirate on admission showed almost normal 
representation of myeloid and megakaryocyte precursors, but erythroid precursors were 
nearly absent. Cytogenetic analysis of the marrow showed a normal female karyotype of 
46 XX. Taken together, a diagnosis of SLE accompanied with PRCA and AIHA was made. 
On the 5th hospital day, the patient was treated with oral prednisolone at a dose of 40 
mg/d. In addition, 3-day intravenous pulse therapy with 500 mg of methylprednisolone 
was added on the 11th, 18th and 25th hospital days. The anemia as well as the 
thrombocytopenia responded well to therapy, resulting in an increase in the hemoglobin 
level of 11.5 g/dl (Figure 1A). Concomitantly, an indirect Coombs’ test became negative 
and, subsequently, a direct Coombs’ test gave a negative result. Follow-up bone marrow 
aspiration revealed the appearance of erythroblasts (46.0% of 18.5×104 nucleated cells).  
As it has been reported that autoantibodies to erythropoietin can be detected in 
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patients with SLE and/or PRCA [3, 5] and that the frequency of these antibodies is 
significantly higher in patients with severe anemia [5], the mechanisms underlying the 
anemia were examined in our patient using radioimmunoprecipitation assay for serum 
autoantibodies against erythropoietin as described previously [6]. The patient was 
positive for serum anti-erythropoietin autoantibodies before treatment, which 
disappeared 6 months after treatment. 
To further examine the pathogenic role of anti-EPO antibodies, the patient’s serum at 
the time of diagnosis was examined for its ability to inhibit EPO-induced cell 
proliferation. The EPO-dependent human erythroid cell line, AS-E2, was cultured in the 
presence of human EPO with the patient’s serum or those from healthy controls [6, 7]. 
The serum from the patient inhibited proliferation of an EPO-dependent cell line in a 
dose-dependent manner, indicating the presence of EPO-neutralizing activity (Figure 
1B). To evaluate the possibility of antierythrocyte antibody action against the 
differentiation and proliferation of erythroid progenitor cells, the patient’s sera positive 
or negative for indirect Coombs’ test, both of which were negative for anti-EPO 
antibodies, were examined for its ability to inhibit the EPO-induced proliferation of 
AS-E2. Unexpectedly, the patient’s sera, positive or negative for the Coombs’ test, 
similarly inhibited EPO-dependent cell proliferation (Figure 1C), suggesting the 
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 This is the first report of the presence of autoantibodies to EPO and functional 
evidence in an SLE patient with combined PRCA and AIHA. According to the revised 
American College of Rheumatology criteria for SLE incorporating hemocytopenia [4], 
hematological abnormalities are common features of this disease [1]. Among these 
manifestations, anemia is found in about 50% of patients, with chronic anemia being 
the most common form [2]. While AIHA occurs in 7–15% of the patients, iron deficiency 
anemia, drug-induced myelotoxicity and anemia of chronic renal failure have also been 
reported [1]. On the other hand, PRCA associated with SLE is rare [2]. The combination 
of PRCA with AIHA in a patient with SLE was first described by Meyer et al. in 1978 [8]. 
Since then, there has been only 1 case in which anti-EPO antibodies were detected [5, 9]. 
Therefore, we have summarized these patients in Table 1. 
 One of the causes of EPO resistance is the presence of antibodies against EPO, which 
inhibit binding of EPO to its receptors and interfere with the differentiation of erythroid 
progenitor cells [3]. In a recent study, anti-EPO antibodies were detected in SLE 
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patients mainly with severe anemia and active disease [5]. In addition, it has been 
reported that the frequency of anti-EPO antibodies in patients with SLE is about 15% 
[5] and that in SLE patients with anemia is 21% [10]. On the other hand, another study 
reported that 46% of patients with SLE have anti-EPO antibodies but at least a 
significant proportion of these antibodies in SLE were not functional, since there was no 
relation to the degree of anemia [11]. Thus, its functional role in inducing anemia in 
SLE has not been elucidated. In the present study, we demonstrated that the patient’s 
serum contained anti-EPO antibodies blocked the proliferation of an EPO-dependent 
cell line in a dose-dependent manner, and that interferon-γ and tumor necrosis factor-
α, proinflammatory cytokines which promoted an apotosis of erythroid progenitor cells 
(data not shown). In addition, antierythrocyte antibodies which could interfere with the 
differentiation and proliferation of erythroid progenitor cells [8] were not detected in the 
serum. Interestingly, existence of putative inhibitor(s) against the erythroid progenitor 
cells in the patient’s serum other than anti-EPO antibodies was suggested. These 
results suggest that anti-EPO antibodies in the present patient have a biological role in 
neutralizing erythropoiesis. 
A blunted EPO response in patients with SLE has been considered to be a leading 
factor in anemia in SLE [11]. Our patient presented with elevated levels of EPO on 
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admission. The presence of anti-EPO antibodies in the patient’s serum was studied by 
the competitive radioimmunoassay (RIA) in the present study. It has been known that 
serum EPO determination by competitive RIA results in the rather high levels of EPO 
due to the existence of antibodies that will compete for tracer binding with antiserum 
used in RIA [6]. On the other hand, Schett et al. reported the EPO levels measured by 
ELISA and the interference by anti-EPO antibodies in the measurement of EPO [11]. 
Taken together, it may be difficult to measure real serum EPO level in anti-EPO 
antibody-positive patients, and a careful interpretation of the EPO level in these 
patients may be required.  
 Our patient responded to immunosuppressive therapy including corticosteroids. As a 
result, the anemia improved gradually accompanied with the disappearance of the 
anti-EPO and antierythrocyte autoantibodies. It has been reported that the presence of 
inhibitory autoantibodies is typically related to SLE activity and can be suppressed by 
successful treatment [2]. Taken together, it is suggested that the coexistence of at least 
two different autoantibodies to the erythroid series contributed to the anemia in our 
patient, as reported previously [12, 13], and that these antibodies were effectively 
regulated by treatment with immunosuppressive drugs. 
 In summary, we described functional evidence of autoantibodies to EPO in an SLE 
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patient with PRCA and AIHA. This case may provide a basis for the pathogenesis of the 
immune-mediated anemia in SLE and for further investigation of the regulation of 
erythropoiesis in hematological disorders. 
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A. Clinical course of the patient and response to treatment. Reticulocyte percentage and  
hemoglobin levels are reported in the graph. Abbreviations: PSL, prednisolone; mPSL,  
methylprednisolone; MZB, mizoribine. 
B. Neutralization of erythropoietin activity by the anti-erythropoietin antibodies in the 
patient’ serum studied by inhibition of proliferation of the erythropoietin-dependent cell 
line, AS-E2. Normal control (○), patient’s serum before treatment (■), patient’s serum 
after treatment (□). 
C. Effect of the patient’s serum positive or negative for the indirect Coombs’ test on the 
proliferation of AS-E2 cells. patient’s serum negative for Coombs’ test (■), patient’s 
serum positive for Coombs’ test (◆) 
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